SEARCH

SEARCH BY CITATION

References

  • 1
    Burge P, Calverley P, Jones P, Spencer S, Anderson J, Maslen T. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 12971303.
  • 2
    Cumming RG, Mitchel P, Leeder S. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 814.
  • 3
    Faul JL, Tormey W, Burke C. High dose inhaled corticosteroids and dose dependant loss of diabetic control. BMJ 1999; 317: 1491.
  • 4
    Pauwels RA, Lofdal CG, Laitinen LA et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue to smoke. N Engl J Med 1999; 340: 19481953.
  • 5
    Wong CA, Walsh LJ, Smith CJP et al. Inhaled corticosteroids use and bone-mineral density in patients with asthma. Lancet 2000; 355: 13991403.
  • 6
    Falcoz C, Oliver R, McDowall J, Ventresca P, Bye A, Daley-Yates P. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet 2000; 39 (Suppl. 1): 915.
  • 7
    Brutsche MH, Carlen Brutsche I, Munawer M et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556561.
  • 8
    The COPD Guideline Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997; 52 (Suppl. 5): S1S28.
  • 9
    Dekhuijzen PN, Honour JW. Inhaled corticosteroids and the hypothalamic–pituitary–adrenal (HPA) axis: do we understand their interaction ? Respir Med 2000; 94: 627631.
  • 10
    Weiner P, Berar-Yaney N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest 1999; 116: 931934.
  • 11
    Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38: 521525.
  • 12
    Grahnen A, Jansson B, Brundin RM et al. A dose–response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbohaler. Eur J Clin Pharmacol 1997; 52: 261267.
  • 13
    Lonnebo A, Grahnen A, Jansson B, Brundin RM, Ling-Andersson A, Eckernas SA. Assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49: 459463.
  • 14
    Thorssom L, Dahlstrom K, Edsbacker A, Kallen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43: 155161.
  • 15
    Yanai M, Hatazawa J, Ojima F, Sasaki H, Itoh M, Ido T. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 11: 13421348.
  • 16
    Harrison TW, Wiseiewski A, Honour J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001; 56: 186191.